Panobinostat: Phase Ib data

In an open-label, dose-escalation Phase Ib trial in 38 evaluable patients, panobinostat plus Velcade bortezomib produced 26 (68%) tumor responses, with 4 complete responses and 22 partial responses, plus 3 cases of stable disease. In a subgroup of Velcade-refractory patients (n=13), panobinostat plus Velcade produced 8 (62%) tumor responses, with 6 partial responses and 2 minor responses. Dose-limiting toxicities included neutropenia, thrombocytopenia, pneumonia, fatigue, asthenia and dizziness. Patients received 10, 20, 25 or 30 mg oral panobinostat thrice weekly and 1 or 1.3 mg/m 2 IV Velcade on days 1, 4, 8 and 11 of a 21-day cycle. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...